EarningsQ2 2026 Earnings Report
DE:SOL0 Q2 2026 EPS Results
Actual EPS€0.06
Consensus EPS€0.05
Beat/MissBeat by +€0.01
One Year Ago EPS€0.09
DE:SOL0 Q2 2026 Revenue Results
Actual Revenue€1.18B
Expected Revenue€1.05B
Beat/MissBeat by +€132.58M
YoY Revenue Growth-3.43%
Earnings Announcement Details
QuarterQ2 2026
Date07/29/2026
TimeBefore Open
Conference CallWednesday, July 29, 2026
DE:SOL0 Upcoming Earnings
Solvay's next earnings date is estimated for November 4, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
DE:SOL0 Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presented a mixed picture: clear strategic progress (record bicarbonate and electronic‑grade peroxide demand, rare‑earth investments and contracts, confirmed 2026 guidance, cost savings and a maintained investment‑grade rating) contrasted with significant near‑term operational headwinds (7% sales decline, 20% EBITDA decline, temporary EUR 20m hit from the Middle East plant shutdown, weak soda ash seaborne markets, modest H1 free cash flow and substantial transformation cash costs). Management confirmed guidance and is prioritizing long‑term transformation and selective growth, but near‑term metrics remain under pressure.Company Guidance
Record demand in bicarbonate and electronic‑grade peroxides
Management reported record sales levels for bicarbonate and for electronic‑grade hydrogen peroxide (driven by semiconductor/AI demand). Electronic‑grade growth helped mitigate weaker volumes elsewhere.
Confirmed 2026 guidance and restart assumptions
Company reiterated full‑year 2026 guidance: underlying EBITDA guidance of EUR 770–850 million, free cash flow to Solvay shareholders > EUR 200 million, and CapEx around EUR 300 million. Guidance assumes restart of peroxides (HPPO) plant in Saudi before end of Q3.
Cost savings and structural efficiency gains
Delivered EUR 26 million of cost savings in Q2 via operational excellence and structural initiatives. Fixed cost discipline more than offset inflationary pressures during the quarter.
Progress and commitment in rare earth strategy
Rare earth remains a strategic focus: rare earth business ~8% of group sales (about half of Special Chem). Company started NdPr production in April 2025, signed LOI with Viridis for Brazilian feedstock (deliveries from 2028), and is investing an additional EUR 15–20 million to add heavy rare earth (DyTb) separation with industrial scale production targeted fall 2026. Management expects total rare earth CapEx to reach EUR 50–100 million over time and noted some governmental and customer prefinancing support.
Balance sheet and credit rating maintained
Underlying net debt EUR 1.8 billion at end‑June; leverage temporarily above 2x but expected to return to around 2x by year‑end. S&P confirmed BBB‑ investment grade rating (June).
Operational readiness and HSE focus
Reportable injury rate improved in Q2 and company emphasized strengthened safety culture and targeted HSE initiatives (hand injuries, slips/trips/falls, contractor safety). CapEx disciplined with H1 CapEx ~EUR 140 million focused on HSE, maintenance and energy transition.
Resilience in certain businesses and sequential recovery
Underlying net sales were up sequentially in all business units despite YoY pressure. Coatis showed sequential improvement and bicarbonate volumes/pricing were broadly stable YoY.
DE:SOL0 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed